Ex-Sanofi exec Whitaker lands at Valeant in EVP role

Sanofi's ($SNY) former North American pharma president, Anne Whitaker, has found yet another new place to call home. After departing from the French drug giant last year for the CEO's chair at Synta Pharmaceuticals ($SNTA)--a move that came amid tough times for Sanofi's flagship diabetes business--she's now moving on to Valeant ($VRX), where she'll step into the role of EVP and group chairman. Release | More

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.